Gilead Sciences, Inc. (GILD)
Why Gilead Sciences (GILD) Outpaced the Stock Market Today
Gilead Sciences (GILD) reached $131.14 at the closing of the latest trading day, reflecting a +1.57% change compared to its last close.
Gilead Sciences: Margin Expansion And Cash Flow Strength Underpriced
Gilead Sciences is undervalued, with a Buy rating and a DCF-based target price of $141, implying 13.4% upside. Core HIV business remains stable, while new product launches and acquisitions, notably Livdelzi, drive incremental growth and diversification. Q3 2025 results exceeded expectations, with revenue up 4% YoY and non-GAAP EPS up 22%, highlighting strong operational efficiency and margin expansion.
Gilead: A Top GARP Biotech Play, But Momentum Weakens (Downgrade)
Gilead Sciences is downgraded from "Strong Buy" to "Buy" as technical momentum has softened despite robust fundamentals. Q3 results exceeded expectations, with EPS of $2.47 and revenue of $7.8 billion, driven by HIV franchise outperformance. GILD guides for 2025 sales of $28.4–$28.7 billion and EPS of $8.05–$8.25, with HIV revenue forecast above $20B and a strong pipeline.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth Knowing
In the most recent trading session, Gilead Sciences (GILD) closed at $122.59, indicating a +1.23% shift from the previous trading day.
Gilead Sciences: From All-Time Highs To Higher Highs
Gilead has successfully launched Yeztugo, the successor to its blockbuster Biktarvy. Gilead expects Yeztugo sales to reach $100 million in Q4, even though it was only approved by the FDA on June 18 last year. Even weak sales of the oncology franchise in Q3 didn't prevent Gilead's EBIT margin from reaching a three-year high of 45.2%.
Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors
Gilead Sciences (GILD) concluded the recent trading session at $118.3, signifying a -2.71% move from its prior day's close.
3 Cash-Flow Machines Investors May Want Heading Into 2026
Of the host of financial metrics investors might consider when deciding whether to buy shares of a target company, cash flow is among the most important. Operating cash flow is a reflection of how a firm actually functions on a day-to-day basis and demonstrates the company's ability to bring in money from sales or other sources and to adequately pay salaries, taxes, and other expenses.
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today
In the latest trading session, Gilead Sciences (GILD) closed at $123.18, marking a -1.38% move from the previous day.
GILD Exercises Option to License Assembly Bio's Herpes Programs
Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.
